Format

Send to

Choose Destination
Eur J Med Genet. 2019 Aug;62(8):103680. doi: 10.1016/j.ejmg.2019.103680. Epub 2019 May 22.

Coexistence of schwannomatosis and glioblastoma in two families.

Author information

1
CHU Bordeaux, Service de Génétique Médicale, Bordeaux, France.
2
CHU Bordeaux, Service de Génétique Médicale, Bordeaux, France; Laboratoire MRGM, INSERM U1211, Univ. Bordeaux, Bordeaux, France. Electronic address: julien.van-gils@chu-bordeaux.fr.
3
CHU Bordeaux, Service de Neurochirurgie, Bordeaux, France.
4
CHU Bordeaux, Service d'orthopédie, Bordeaux, France.
5
CHU Bordeaux, Service de Médecine Physique et Réadaptation, Bordeaux, France.
6
Service de Génétique et Biologie Moléculaires, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
7
Service de Génétique et Biologie Moléculaires, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France; UMR INSERM 1016, Institut Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
8
CHU Bordeaux, Service de Génétique Médicale, Bordeaux, France; Laboratoire MRGM, INSERM U1211, Univ. Bordeaux, Bordeaux, France.

Abstract

Schwannomatosis is a rare affection predisposing to multiple peripheral neurologic tumors development. Approximatively, one third of patients with schwannomatosis are carriers of a germline mutation in LZTR1 (Leucin Zipper Transcription Regulator 1). Tumorigenesis in schwannomatosis responds to a somatic 5-hit/3-step mechanism resulting in a loss of function (LOF) of LZTR1 and the contiguous genes of locus 22q11.2q12.2. Effectively, LZTR1 is mapped on 22q11.2 and centromeric to SMARCB1 also implicated in the determinism of schwannomatosis and NF2, responsible for neurofibromatosis type 2. On a somatic point of view, LZTR1 mutations are known to drive with a significant frequency glioblastoma (GB) development. We report here two families in which segregate both multiple schwannomas and GB. In the first family, the proband received a diagnosis with of schwannomatosis after a surgery for a lumbar schwannoma at age 43, molecularly confirmed by identification of a germline heterozygous mutation in LZTR1. Her father, having unremarkable medical history deceased from an apparently isolated GB at age 59. In the second family, LZTR1-related schwannomatosis was diagnosed in the index case at age 70 after multiple schwannomas surgeries. Her elder sister had no neurological medical history before occurrence of a lethal GB at age 78. Molecular analysis of GB sample from both affected relatives showed the presence of the familial mutation. These observations hypothesize a potential link between schwannomatosis and the GB development.

KEYWORDS:

Glioblastoma; LZTR1; Neurofibromatosis; SMARCB; Schwannomatosis

PMID:
31128261
DOI:
10.1016/j.ejmg.2019.103680
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center